Eziafa Oduah, Md, Phd, Mph

This study looked at adding evolocumab (a cholesterol-lowering drug) to standard immunotherapy (nivolumab and ipilimumab) for people with advanced non-small cell lung cancer who had not received prior treatment. The goal was to see if the combination was safe and could improve th…